Log In
Print
BCIQ
Print
Print this Print this
 

Trisenox, arsenic trioxide

Also known as: ATO

  Manage Alerts
Collapse Summary General Information
Company Teva Pharmaceutical Industries Ltd.
DescriptionArsenic trioxide that causes DNA fragmentation and damage to promyelocytic leukemia-retinoic acid receptor alpha (PML-RARA) fusion protein
Molecular Target DNA
Mechanism of ActionUnknown
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationAcute promyelocytic leukemia (APL)
Indication DetailsTreat acute promyelocytic leukemia (APL); Treat refractory acute promyelocytic leukemia (APL); Treat relapsed or refractory acute promyelocytic leukemia (APL)
Regulatory Designation Australia - Orphan Drug (Treat acute promyelocytic leukemia (APL))
Partner H. Lundbeck A/S; Nippon Shinyaku Co. Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today